Medtronic Surgical Technologies
15
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
46.7%
7 terminated/withdrawn out of 15 trials
53.3%
-33.2% vs industry average
0%
0 trials in Phase 3/4
125%
10 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Novapak Prospective Observational Clinical Trial
Role: lead
Ambispective Clinical Evaluation of Sophono™
Role: lead
Bipolar Sealer Aquamantys Use in Total Knee Replacement
Role: lead
Surgical / Economic Effect of the Aquamantys System in Blood Management for Aseptic and Septic Revision TKA
Role: lead
Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade
Role: collaborator
A Registry Study Evaluating Outcomes in Breast Biopsy With the Intact™ Breast Lesion Excision System (BLES)
Role: lead
NuVent™ Revision Study
Role: lead
PEAK PlasmaBlade 4.0 Versus Traditional Electrosurgery in Total Knee Replacement.
Role: lead
PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy
Role: lead
PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Mastectomy
Role: lead
A Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0
Role: lead
Use of the PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction
Role: lead
PEAK PlasmaBlade TnA Versus Traditional Electrosurgery in Subcapsular Tonsillectomy
Role: lead
PEAK PlasmaBlade™ vs. Traditional Electrosurgery in Abdominoplasty
Role: lead
PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction
Role: lead
All 15 trials loaded